Get the Stockscreener App
0.1809
28.84%
-0.0733
Profusa Inc stock is traded at $0.1809, with a volume of 14.43M.
It is down -28.84% in the last 24 hours and down -58.55% over the past month.
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
See More
Previous Close:
$0.2542
Open:
$0.1839
24h Volume:
14.43M
Relative Volume:
3.06
Market Cap:
$843.04K
Revenue:
$75,000
Net Income/Loss:
$-42.41M
P/E Ratio:
-0.00101
EPS:
-179.8206
Net Cash Flow:
$-18.47M
1W Performance:
-33.57%
1M Performance:
-58.55%
6M Performance:
-97.86%
1Y Performance:
+0.00%
1-Day Range:
$0.1706
$0.1979
1-Week Range:
$0.1706
$0.2699
52-Week Range:
$0.1706
$166.50
Profusa Inc Stock (PFSA) Company Profile
Name
Profusa Inc
Sector
Industry
Phone
212-494-9022
Address
207 WEST 25TH ST, 9TH FLOOR, NEW YORK
Compare PFSA vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFSA
Profusa Inc
|
0.1809 | 843.04K | 75,000 | -42.41M | -18.47M | -179.82 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Profusa Inc Stock (PFSA) Latest News
Why Did PFSA Stock Surge 150% Today? - Stocktwits
Profusa submits response to European regulator for device approval - Investing.com UK
Profusa submits response to European regulator for device approval By Investing.com - Investing.com Canada
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform - The Manila Times
Profusa Submits Response Package to GMED as Part of Ongoing Ce Mark Review Process for Lumee Oxygen Platform - marketscreener.com
Profusa CEO urges shareholders to vote on Nasdaq listing proposals By Investing.com - Investing.com Nigeria
Profusa CEO urges shareholders to vote on Nasdaq listing proposals - Investing.com
Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting - The Manila Times
Profusa Issues Letter to Shareholders Encouraging - GlobeNewswire
Profusa, Inc. Files 8-K: Advance Notice for Common Stock Purchase Under Equity Line Agreement with Ascent Partners, Nasdaq Listed (PFSA) - Minichart
Profusa (NASDAQ: PFSA) registers 179.3M shares; Ascent holds majority - Stock Titan
Profusa Taps Equity Line With Dilutive True-Up Mechanism - TipRanks
Profusa secures temporary equity purchase terms with Ascent under amended SPA - TradingView
Profusa (PFSA) adjusts Ascent equity line with caps, VWAP and true-up terms - Stock Titan
Profusa (PFSA) affiliates report 9.99% ownership; reorg adds Eagle Claw - Stock Titan
Profusa to acquire multi-omics platform, partners with Mayo Clinic - Investing.com
PFSA Stock Chart | PROFUSA INC (NASDAQ:PFSA) - ChartMill
PFSA Technical Analysis | Trend, Signals & Chart Patterns | PROFUSA INC (NASDAQ:PFSA) - ChartMill
Profusa Inc. (PFSA) Slips 3.56% as Stock Approaches Key Support at $0.33Fibonacci Arc - The Legal Advocate
Profusa Shares Below 40 Cents as Nasdaq Deadline Nears - Bez Kabli
Profusa Inc. (PFSA) Slides 4.7% as Stock Tests Key Support at $0.33Ending Diagonal - newsline.com
Profusa Inc. (PFSA) Facing Resistance at $0.38 as Shares Dip 3.21%Volume Breakout Ideas - newsline.com
PFSA | Profusa, Inc. Common Stock Executive Compensation - Quiver Quantitative
[ARS] Profusa, Inc. SEC Filing - Stock Titan
Profusa (NASDAQ: PFSA) eyes major reverse split, $30M PanOmics stock acquisition and note conversion - Stock Titan
Profusa Amends PanOmics Acquisition Terms to Reduce Dilution - TipRanks
Profusa Amends $30 Million Asset Purchase of PanOmics Assay, Drops 12% Management Equity Grant - TradingView
[8-K] Profusa, Inc. Reports Material Event - Stock Titan
Profusa Inc. (PFSA) Edges Higher, Testing Key Resistance at $0.40Low Volatility Picks - The Legal Advocate
PFSA Should I Buy - Intellectia AI
Profusa, Inc. Submits Advance Notice for Equity Line Share Purchase with Ascent Partners Fund LLC – SEC Filing 8-K May 18, 2026 - Minichart
Profusa submits equity purchase notice to Ascent Partners under credit agreement - Investing.com Nigeria
Profusa (NASDAQ: PFSA) registers 179.3M resale shares; Ascent equity line terms detailed - Stock Titan
Profusa Taps Equity Line for Near-Term Liquidity - TipRanks
Profusa submits advance notice to Ascent for up to 9.99% equity purchase with true-up mechanism - TradingView
Profusa (NASDAQ: PFSA) details May equity line share purchase terms - Stock Titan
Number of shareholders of Profusa, Inc. – NASDAQ:PFSA - TradingView
Profusa Transfers Nasdaq Listing Amid Ongoing Compliance Uncertainty - The Globe and Mail
PFSA Financials: Income Statement, Balance Sheet & Cash Flow | Profusa Inc - Stock Titan
Profusa, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Profusa (NASDAQ: PFSA) Q1 2026 loss deepens amid going concern and Nasdaq listing pressure - Stock Titan
Profusa, Inc. Announces Transfer to Nasdaq Capital Market to Ensure Continued Listing Compliance - Minichart
Profusa to Transfer Listing to The Nasdaq Capital Market Effective May 15, 2026 - TradingView
Profusa (Nasdaq: PFSA) shifts stock listing to Nasdaq Capital Market tier - Stock Titan
Profusa moves to Nasdaq Capital Market amid compliance efforts By Investing.com - Investing.com Australia
Profusa moves to Nasdaq Capital Market amid compliance efforts - Investing.com
Profusa Announces Listing Transfer to The Nasdaq Capital Market - The Manila Times
Profusa announces listing transfer to the Nasdaq Capital Market - marketscreener.com
Digital health company Profusa shifts Nasdaq tier to meet listing rules - Stock Titan
Profusa granted transfer to Nasdaq Capital Market, faces July compliance deadline - MSN
Profusa Inc Stock (PFSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):